MDS/MPN

Indeling (WHO 2022)

• Chronische myelomonocytische leukemie (CMML)

• Myelodysplastic/myeloproliferative neoplasm with neutrophilia

  • WHO 2016: atypische CML

• Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis

  • WHO 2016: MDS/MPN met ringsideroblasten en trombocytose

• Myelodysplastic/myeloproliferative neoplasm, not otherwise specified

WHO 2022

This category of myeloid neoplasms is defined by overlapping pathologic and molecular features of MDS and MPN, often manifesting clinically with various combinations of cytopenias and cytoses.

Cytopenia definitions are harmonized for CCUS, MDS, and MDS/MPN; they include

• Hb <13 g/dL(<7.8 mmol/L) in males and <12 g/dL (<7.2 mmol/l) in females for anaemia;

• absolute neutrophil count <1.8 10E9/L for leukopenia;

• platelets <150 10E9/L for thrombocytopenia.